Travere Therapeutics (TVTX) Tax Provisions (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly Tax Provisions came in at -$120000.0 in Q1 2026, down 407.69% YoY from $39000.0 in Q1 2025, and down 113.03% on a QoQ basis from $921000.0 in Q4 2025.
Travere Therapeutics (TVTX) Tax Provisions (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of Tax Provisions data on file, last reported at -$120000.0 in Q1 2026.
- Quarterly Tax Provisions fell 407.69% year-over-year to -$120000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $829000.0 (up 2690.62% YoY) and the FY2025 annual result came in at $988000.0, up 723.33% from the prior year.
- Tax Provisions declined to -$120000.0 in Q1 2026, from $921000.0 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $921000.0 in Q4 2025 to a low of -$120000.0 in Q1 2026.
- A 5-year average of $89647.1 and a median of $53000.0 in 2022 frame the typical range for Tax Provisions.
- Annual changes were most pronounced in 2022 — Tax Provisions jumped 1475.0% — and 2024, when it plunged 800.0%.
- Tracing TVTX's Tax Provisions over 5 years: stood at $63000.0 in 2022, then rose by 7.94% to $68000.0 in 2023, then sank by 205.88% to -$72000.0 in 2024, then soared by 1379.17% to $921000.0 in 2025, then slumped by 113.03% to -$120000.0 in 2026.
- The last three Tax Provisions figures came in at -$120000.0 (Q1 2026), $921000.0 (Q4 2025), and $8000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | -204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -204,000.00 |
| Mar 31, 2026 | -120,000.00 |
| Dec 31, 2025 | 921,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 39,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | -84,000.00 |
| Jun 30, 2024 | 85,000.00 |
| Mar 31, 2024 | 191,000.00 |
| Dec 31, 2023 | 68,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 65,000.00 |
| Mar 31, 2023 | 78,000.00 |
| Dec 31, 2022 | 63,000.00 |
| Sep 30, 2022 | 145,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Mar 31, 2022 | 52,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 43,000.00 |